Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know

Johnson & Johnson (JNJ) shares returned -0.1% over the past month, underperforming the S&P 500 but aligning with its industry. Analysts project current quarter EPS at $2.78 (+14.9% YoY) and current fiscal year EPS at $10.86 (+8.8% YoY), alongside robust revenue growth forecasts, building on a consistent track record of beating consensus estimates. Despite a Zacks Rank #3 (Hold) suggesting near-term market-average performance, JNJ holds a Zacks Value Style Score of 'B', indicating it trades at a discount relative to its peers.

Analysis

Johnson & Johnson (JNJ) presents a mixed but fundamentally solid profile for investors. The stock has recently underperformed the broader market, returning -0.1% over the past month compared to the S&P 500's +2.7% gain, though it has tracked its Large Cap Pharmaceuticals peer group. Despite this lackluster price action, the company's operational outlook appears robust. Analyst consensus projects significant earnings growth, with current quarter EPS expected to rise 14.9% year-over-year to $2.78 and full-year EPS to grow 8.8% to $10.86. These estimates have remained stable, indicating analyst confidence, while the estimate for the next fiscal year has seen a slight upward revision of +0.1%. This is supported by consistent revenue growth forecasts of +5.6% for the current quarter and +5.2% for the fiscal year. JNJ's execution is strong, evidenced by a track record of beating both EPS and revenue consensus estimates for the last four consecutive quarters, including a recent 4.14% EPS surprise. Furthermore, a Zacks Value Style Score of 'B' suggests the stock is currently trading at a discount to its peers. However, this positive fundamental picture is tempered by a Zacks Rank of #3 (Hold), which implies the stock is likely to perform in line with the market in the near term, reflecting the current stagnation in earnings estimate revisions.

Key Decisions for Investors

• Given Johnson & Johnson's consistent earnings beats and a 'B' value score indicating a discount to peers, value-oriented investors might consider the recent stock underperformance as an attractive entry point for a long-term position.
• Investors seeking near-term alpha should note the Zacks Rank #3 (Hold) and stagnant share price, which suggest the stock may continue to perform in line with the market until a new catalyst or significant upward earnings estimate revisions emerge.
• It is prudent to monitor for any changes in consensus earnings estimates, as the article highlights this as a primary driver for the stock's rating and a potential signal for an inflection in its short-term price movement.